A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the mycobactericidal activity, safety, tolerability,
and pharmacokinetics of 6 doses of linezolid: 300 mg once per day, 300 mg twice per day, 600
mg once per day, 600 mg twice per day and 1200 mg once per day administered orally for 14
consecutive days or 1200 mg administered three times per week for two weeks in adult subjects
with newly diagnosed drug-sensitive, smear-positive pulmonary tuberculosis.